Menu
ÚHKT

doc. MUDr. Iuri Marinov, CSc.

vedoucí laboratoře průtokové cytometrie

Tel: +420 221 977 458, +420 221 977 337
Email: Iuri.Marinov@uhkt.cz

Impaktované publikace

[1]

Rawstron, A.C.; Fazi, C.; Agathangelidis, A.; Villamor, D.; Letestu, R.; Nomdedeu, J.; Palacio, C.; Stehlikova, O.; Kreuzer, K.-A.; Liptrot, S.; O'Brien, D.; De Tute, R.M.; Marinov, I.; Hauwel, M.; Spacek, M.; Dobber, J.; Kater, A.P.; Gambell, P.; Soosapilla, A.; Lozanski, G.; Brachtl, G.; Lin, K.; Boysen, J.; Hanson, C.; Jorgensen, J.L.; Stetler-Stevenson, M.; Yuan, C.; Broome, H.E.; Rassenti, L.; Craig, F.; Delgado, J.; Moreno, C.; Bosch, F.; Egle, A.; Doubek, M.; Pospisilova, S.; Mulligan, S.; Westerman, D.; Sanders, C.M.; Emerson, R.; Robins, H.S.; Kirsch, I.; Shanafelt, T.; Pettitt, A.; Kipps, T.J.; Wierda, W.G.; Cymbalista, F.; Hallek, M.; Hillmen, P.; Montserrat, E.; Ghia, P.

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study

[rok vydání 2016, impact factor 11.702 ]

[2]

Bene, M.C.; Nebe, T.; Bettelheim, P.; Buldini, B.; Bumbea, H.; Kern, W.; Lacombe, F.; Lemez, P.; Marinov, I.; Matutes, E.; Maynadie, M.; Oelschlagel, U.; Orfao, A.; Schabath, R.; Solenthaler, M.; Tschurtschenthaler, G.; Vladareanu, A.M.; Zini, G.; Faure, G.C.; Porwit, A.

Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10

[rok vydání 2011, impact factor 9.561 ]

[3]

Motovska, Z.; Widimsky, P.; Petr, R.; Bilkova, D.; Marinov, I.; Simek, S.; Kala, P.

Optimal pretreatment timing for high load dosing (600 mg) of clopidogrel before planned percutaneous coronary intervention for maximal antiplatelet effectiveness

[rok vydání 2010, impact factor 6.802]

[4]

Béné, M.C.; Castoldi, G.; Derolf, A.; Garand, R.; Haas, T.; Haferlach, T.; Knapp, W.; Kuhlein, E.; Lemež, P.; Ludwig, W.D.; Marinov, I.; Matutes, E.; Michalová, K.; Porwit-MacDonald, A.; Orfao, A.; Schoch, C.; Talmant, P.; Van´t Veer, M.B.; Zemanová, Z.; Zühlsdorf, M.

Near-tetraploid acute myeloid leukemias : an EGIL retrospective study of 25 cases

[rok vydání 2007, impact factor 6.146]

[5]

Smahel, M.; Sobotkova, E.; Bubenik, J.; Simova, J.; Zak, R.; Ludvikova, V.; Hajkova, R.; Kovarik, J.; Jelinek, F.; Povysil, C.; Marinov, Y.; Vonka, V.

Metastatic MHC class I-negative mouse cells derived by transformation with human papillomavirus type 16

[rok vydání 2006, impact factor 3.942]

[6]

Štulc, T.; Vrablík, M.; Kasalová, Z.; Češka, R.; Marinov, I.

Atorvastatin reduces expression of leukocyte adhesion molecules in patients with hypercholesterolemia

[rok vydání 2006, impact factor 3.603]

[7]

Kuželová, K.; Grebeňová, D.; Marinov, I.; Hrkal, Z.

Fast apoptosis and erythroid differentiation induced by Imatinib mesylate in JURL-MK1 cells.

[rok vydání 2006, impact factor 3.591]

[8]

Valkova, V.; Vydra, J.; Markova, M.; Cerovska, E.; Vrana, M.; Marinov, I.; Cechova, H.; Cetkovsky, P.; Vitek, A.; Salek, C.

WT1 gene expression in peripheral blood before and after allogeneic stem cell transplantation is a clinically relevant prognostic marker in AML: a single-center 14-year experience

[rok vydání 2020, impact factor 3.231 ]

[9]

Sutherland, D.R.; Richards, S.J.; Ortiz, F.; Nayyar, R.; Benko, M.; Marinov, I.; Illingworth, A.

CD71 improves delineation of PNH type III, PNH type II, and normal immature RBCS in patients with paroxysmal nocturnal hemoglobinuria

[rok vydání 2019, impact factor 3.058 ]

[10]

Písačka, M.; Marinov, I.; Králová, M.; Králová, J.; Kořánová, M.; Bohoněk, M.; Sood, C.; Ochoa-Garay, G.

FY*A silencing by the GATA-motif variant FY*A(-69C) in a Caucasian family

[rok vydání 2015, impact factor 3.042 ]

[11]

Šmahel, M.; Šíma, P.; Ludvíková, V.; Marinov, I.; Pokorná, D.; Vonka, V.

Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules

[rok vydání 2006, impact factor 3.007]

[12]

Marinov, I.; Kohoutová, M.; Tkáčová, V.; Pešek, A.; Čermák, J.; Cetkovský, P.

Performance characteristics of consensus approaches for small and minor paroxysmal nocturnal hemoglobinuria clone determination by flow cytometry

[rok vydání 2013, impact factor 2.955 ]

[13]

Provaznikova, D.; Rittich, S.; Malina, M.; Seeman, T.; Marinov, I.; Riedl, M.; Hrachovinova, I.

Manifestation of atypical hemolytic uremic syndrome caused by novel mutations in MCP.

[rok vydání 2011, impact factor 2.939 ]

[14]

Marinov, I.; Illingworth, A.J.; Benko, M.; Sutherland, D.R.

Performance characteristics of a non-fluorescent aerolysin-based paroxysmal nocturnal hemoglobinuria (PNH) assay for simultaneous evaluation of PNH neutrophils and PNH monocytes by flow cytometry, following published PNH guidelines

[rok vydání 2016, impact factor 2.938 ]

[15]

Sutherland, D.R.; Ortiz, F.; Quest, G.; Illingworth, A.; Benko, M.; Nayyar, R.; Marinov, I.

High-sensitivity 5-, 6-, and 7-color PNH WBC assays for both Canto II and Navios platforms

[rok vydání 2018, impact factor 2.938 ]

[16]

Sutherland, D.R.; Illingworth, A.; Marinov, I.; et al.

ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 2: reagent selection and assay optimization for high-sensitivity testing

[rok vydání 2018, impact factor 2.938 ]

[17]

Motovska, Z.; Widimsky, P.; Petr, R.; Bilkova, D.; Marinov, I.; Simek, S.; Kala, P.

Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention : statin's advantage and the smoking "paradox"

[rok vydání 2010, impact factor 2.826]

[18]

Polivkova, V.; Rohon, P.; Klamova, H.; Cerna, O.; Divoka, M.; Curik, N.; Zach, J.; Novak, M.; Marinov, I.; Soverini, S.; Faber, E.; Machova Polakova, K.

Interferon-alpha revisited: individualized treatment management eased the selective pressure of tyrosine kinase inhibitors on BCR-ABL1 mutations resulting in a molecular response in high-risk CML patients

[rok vydání 2016, impact factor 2.806 ]

[19]

Uherková, L.; Vančurová, I.; Vyhlídalová, I.; Pleschnerová, M.; Špička, I.; Mihalová, R.; Březinová, J.; Hodný, Z.; Čermáková, K.; Polanská, V.; Marinov, I.; Jedelský, P.L.; Kuželová, K.; Stöckbauer, P.

Novel human multiple myeloma cell line UHKT-893

[rok vydání 2013, impact factor 2.692 ]

[20]

Smahel, M.; Smahelova, J.; Tejklova, P.; Tachezy, R.; Marinov, I.:

Characterization of cell lines derived from tumors induced by TC-1 cells in mice preimmunized against HPV16 E7 oncoprotein.

[rok vydání 2006, impact factor 2.681]

Neimpaktované publikace

[1]

Provaznikova, D.; Peslova, G.; Marinov, I.; Babusiak, M.; Vyoral, D.; Fuchs, O.

The increased expression of SnoN and undetectable levels of important cell cycle regulators, proteins p21Waf1/Cip1 and p27Kip1 as probable causes of the resistance of ML-2 cells proliferation to transforming growth factor-ßETA1

[rok vydání 2007]